Milestone Scientific (MLSS) AI Stock Analysis

• Market Cap: $29.73M
• Dividend Yield: N/A
• Average Volume (3M): 172.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.54
• Revenue Growth: 0.59%
• EPS Growth: -39.76%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.01
• Shares Outstanding: 78,559,150
• 10 Day Avg. Volume: 233,274
• 30 Day Avg. Volume: 172,658
• PEG Ratio: 0.43
• Price to Book (P/B): 13.13
• Price to Sales (P/S): 8.88
• P/FCF Ratio: -26.14
• Enterprise Value/Market Cap: 1.75
• Enterprise Value/Revenue: 5.73
• Enterprise Value/Gross Profit: 7.87
• Enterprise Value/Ebitda: -7.59
• 1Y Price Target: $1.00
• Price Target Upside: 222.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.50 ▲(61.29% Upside)

Milestone Scientific's overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While the earnings call provided some positive sentiment due to strategic initiatives, the company's ongoing financial challenges and negative valuation metrics weigh heavily on the score.

Positive Factors

Cost Management

Effective cost management and operational restructuring can enhance profitability and provide a more sustainable financial position over time.

Expansion in Dental Segment

Expansion in the dental segment, especially internationally, diversifies revenue streams and strengthens market presence, supporting long-term growth.

Medicare Payment Rate Assignments

Securing Medicare payment rates enhances the product's marketability and can drive adoption in the medical segment, boosting future revenues.

Negative Factors

Negative Cash Flow

Persistent negative cash flow indicates operational inefficiencies and can limit the company's ability to invest in growth opportunities.

Decline in Domestic Dental Revenue

A decline in domestic dental revenue suggests potential market saturation or competitive pressures, impacting overall revenue stability.

Negative Return on Equity

A negative return on equity indicates that the company is not efficiently using shareholder investments to generate profits, affecting investor confidence.

Milestone Scientific Business Overview & Revenue Model

Company Description

Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.

How the Company Makes Money

Milestone Scientific generates revenue primarily through the sale of its proprietary injection technology systems and disposable products. Key revenue streams include direct sales of the CompuFlo® and Wand® systems to dental and medical practitioners, as well as recurring revenue from disposable cartridges and accessories required for these systems. Additionally, the company may engage in strategic partnerships with healthcare providers and distributors to expand its market reach. Factors contributing to its earnings include the growing demand for pain management solutions in medical and dental procedures, as well as potential licensing agreements for its technology.

Milestone Scientific Financial Statement Overview

Summary

Milestone Scientific faces significant financial challenges. Despite a strong gross profit margin, the company operates at a loss with negative net profit and cash flow margins. The balance sheet shows low leverage but a concerning negative return on equity. Overall, financial health is weak, necessitating operational improvements.

Income Statement

Milestone Scientific's income statement reveals a challenging financial position. The company has experienced a slight revenue growth of 5.45% in the TTM period, but it continues to operate at a loss with a negative net profit margin of -61.16%. The gross profit margin is relatively strong at 74.37%, indicating efficient cost management in production. However, the negative EBIT and EBITDA margins highlight ongoing operational inefficiencies and high operating expenses.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.07, suggesting a conservative approach to leveraging. However, the return on equity is negative at -82.73%, indicating that the company is not generating sufficient returns on shareholders' investments. The equity ratio stands at 41.48%, reflecting a moderate level of financial stability, but the overall negative ROE is a significant concern.

Cash Flow

Cash flow analysis indicates significant challenges, with a negative operating cash flow and free cash flow. The free cash flow growth rate is positive at 93.82%, but this is from a negative base, indicating volatility. The operating cash flow to net income ratio is negative, suggesting that the company struggles to convert its accounting profits into cash. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is in line with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.08M	8.63M	9.83M	8.81M	10.30M	5.44M
Gross Profit	6.61M	6.43M	6.79M	4.90M	6.31M	3.62M
EBITDA	-6.86M	-6.72M	-7.04M	-8.76M	-7.30M	-7.36M
Net Income	-6.97M	-4.71M	-6.93M	-8.71M	-6.82M	-7.34M
Balance Sheet
Total Assets	8.05M	9.80M	11.37M	13.70M	19.81M	19.57M
Cash, Cash Equivalents and Short-Term Investments	1.27M	3.26M	5.95M	8.72M	14.76M	14.22M
Total Debt	1.09M	349.05K	395.98K	497.04K	586.59K	942.60K
Total Liabilities	4.71M	3.96M	3.36M	3.70M	3.59M	3.46M
Stockholders Equity	3.34M	5.83M	8.01M	10.23M	16.37M	16.20M
Cash Flow
Free Cash Flow	-5.26M	-2.93M	-5.33M	-6.04M	-4.03M	-7.01M
Operating Cash Flow	-5.26M	-2.92M	-5.33M	-6.03M	-4.02M	-6.98M
Investing Cash Flow	-2.98M	2.97M	-2.97M	-8.53K	-15.19K	-21.44K
Financing Cash Flow	789.19K	233.77K	2.56M	-8.54K	4.57M	19.71M

Milestone Scientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.31
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLSS, the sentiment is Negative. The current price of 0.31 is below the 20-day moving average (MA) of 0.35, below the 50-day MA of 0.42, and below the 200-day MA of 0.72, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 34.93 is Neutral, neither overbought nor oversold. The STOCH value of 28.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLSS.

Milestone Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEPH	69 Neutral	$55.12M	41.63	16.29%	―	32.36%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POCI	51 Neutral	$36.18M	-5.52	-57.98%	―	13.67%	-37.01%
FEMY	48 Neutral	$53.80M	―	-376.23%	―	63.53%	12.49%
RVP	48 Neutral	$25.18M	-2.81	-8.05%	―	-0.95%	58.17%
MLSS	41 Neutral	$29.73M	-4.35	-136.47%	―	0.59%	-39.76%
NXGL	41 Neutral	$23.44M	-5.47	-58.34%	―	73.38%	34.87%

Milestone Scientific Corporate Events

Milestone Scientific Inc. Reports Q3 2025 Financial Results

Milestone Scientific Inc., a Delaware-based company, specializes in the development and commercialization of computer-controlled anesthetic delivery devices for dental and medical applications. The company operates primarily in the medical technology sector, with products like the CompuDent® and CompuFlo® systems that are marketed globally.

Milestone Scientific Director Leonard Osser Resigns

On November 7, 2025, Leonard A. Osser resigned as a director of Milestone Scientific Inc., but will continue his involvement through an employment and consulting agreement. This change in leadership may impact the company’s operations and stakeholder relations, as Mr. Osser remains connected to the company in a different capacity.

The most recent analyst rating on (MLSS) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Milestone Scientific stock, see the MLSS Stock Forecast page.

Milestone Scientific Faces NYSE Non-Compliance Notice

On October 8, 2025, Milestone Scientific Inc. received a notice from NYSE American LLC indicating non-compliance with certain listing standards. The company must submit a compliance plan by November 7, 2025, to maintain its listing, with potential delisting if standards are not met by April 8, 2027.

The most recent analyst rating on (MLSS) stock is a Buy with a $1.25 price target. To see the full list of analyst forecasts on Milestone Scientific stock, see the MLSS Stock Forecast page.

Milestone Scientific Reports Increased Sales but Faces Losses

Milestone Scientific Inc., a Delaware-based company, specializes in developing computer-controlled anesthetic delivery devices for dental and medical applications, with a focus on innovative technology in the healthcare sector. In its latest earnings report for the quarter ended June 30, 2025, Milestone Scientific Inc. highlighted a net loss of $1.48 million, compared to a net income of $223,638 in the same quarter of the previous year. The company reported product sales of $2.32 million, a notable increase from $1.85 million in the same period last year, driven by a rise in dental segment sales. Despite an increase in gross profit to $1.62 million, the company faced higher operating expenses, which contributed to the overall loss. Milestone Scientific’s financial performance was impacted by increased selling, general, and administrative expenses, as well as research and development costs. The company continues to face challenges related to its cash flow and liquidity, with cash and cash equivalents decreasing to $1.27 million from $3.26 million at the end of 2024. Looking ahead, Milestone Scientific’s management remains focused on securing additional funding to support its operations and aims to enhance revenue generation from its dental and medical device segments, while also working to reduce operating expenses.